← Leaderboards
Young-Sup Yoon
Emory University
$22,369,229
Attributed
$26,714,909
Total exposure
15
Grants
15
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $6.1M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$26,714,909 · 15
By mechanism
R01$14,640,060 · 8
DP3$8,711,416 · 2
R61$1,084,578 · 1
RC1$1,000,000 · 1
R33$545,998 · 1
R21$426,250 · 1
Top collaborators
- Sang-Ho Lee3 shared
- Xiaodong Cheng2 shared
Most similar at Emory University
Same institution · by research overlap
- Changyi Chen$9,187,725
- Sang-Ho Lee$776,166
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsTherapeutic EffectStem CellsMorbidity - Disease RateCell TherapyEndothelial CellsMolecularIn VivoMyocardial IschemiaNeovascularizationAnimal ModelFunctional DisorderDesignInduced Pluripotent Stem CellBlood VesselsCell TypeBone MarrowAdult Stem CellCardiovascular DiseasesCell LineageGenesResearch PersonnelInsightBiomedical Engineering
Grant awards (45)
Vascular Regeneration with Direct Reprogramming and Engineering Strategies$538,488
R01 · FY2025 · HL · contact PI
Lymphatic Regeneration by Direct Cellular Reprogramming$520,917
R01 · FY2025 · HL · contact PI
Vascular Regeneration with Human Pluripotent Stem Cell-derived Vascular Cells and Engineering Approaches$491,504
R01 · FY2025 · HL · contact PI
Vascular Regeneration with Reprogrammed Endothelial Cells$306,607
R41 · FY2025 · HL · contact PI
Vascular Regeneration with Direct Reprogramming and Engineering Strategies$527,719
R01 · FY2024 · HL · contact PI
Lymphatic Regeneration by Direct Cellular Reprogramming$510,498
R01 · FY2024 · HL · contact PI
Vascular Regeneration with Human Pluripotent Stem Cell-derived Vascular Cells and Engineering Approaches$481,673
R01 · FY2024 · HL · contact PI
Vascular Regeneration with Direct Reprogramming and Engineering Strategies$538,488
R01 · FY2023 · HL · contact PI
Lymphatic Regeneration by Direct Cellular Reprogramming$520,917
R01 · FY2023 · HL · contact PI
Vascular Regeneration with Human Pluripotent Stem Cell-derived Vascular Cells and Engineering Approaches$491,504
R01 · FY2023 · HL · contact PI
Cardiac Revascularization with Direct Reprogramming Approaches$449,136
R01 · FY2023 · HL · contact PI
Human iPSC-derived endothelial cells as Vascular Therapeutics$545,998
R33 · FY2022 · HL · contact PI
Vascular Regeneration with Direct Reprogramming and Engineering Strategies$538,488
R01 · FY2022 · HL · contact PI
Vascular Regeneration with Human Pluripotent Stem Cell-derived Vascular Cells and Engineering Approaches$491,504
R01 · FY2022 · HL · contact PI
Cardiac Revascularization with Direct Reprogramming Approaches$449,136
R01 · FY2022 · HL · contact PI
Human iPSC-derived endothelial cells as Vascular Therapeutics$538,578
R61 · FY2021 · HL · contact PI
Cardiac Revascularization with Direct Reprogramming Approaches$449,136
R01 · FY2021 · HL · contact PI
Human iPSC-derived endothelial cells as Vascular Therapeutics$546,000
R61 · FY2020 · HL · contact PI
Cardiac Revascularization with Direct Reprogramming Approaches$463,136
R01 · FY2020 · HL · contact PI
Cardiac Regeneration with Bioengineered Human Stem Cells$387,072
R01 · FY2019 · HL · contact PI
Stem Cell-based therapy for Lymphedema$387,072
R01 · FY2018 · HL · contact PI
Cardiac Regeneration with Bioengineered Human Stem Cells$387,072
R01 · FY2018 · HL · contact PI
Cardiac Regeneration with Bioengineered Human Stem Cells$401,072
R01 · FY2017 · HL · contact PI
Stem Cell-based therapy for Lymphedema$387,072
R01 · FY2017 · HL · contact PI
Stem Cell-based therapy for Lymphedema$401,072
R01 · FY2016 · HL · contact PI
Cardiac Regeneration with Bioengineered Human Stem Cells$390,000
R01 · FY2016 · HL · contact PI
Effects of reprogrammed and engineered MSCs on diabetic complications$147,430
DP3 · FY2016 · DK · contact PI
Effects of reprogrammed and engineered MSCs on diabetic complications$2,424,957
DP3 · FY2015 · DK · contact PI
Stem Cell-based therapy for Lymphedema$390,000
R01 · FY2015 · HL · contact PI
Cell therapy for diabetic peripheral neurovascular complications$6,139,029
DP3 · FY2011 · DK · contact PI
Generation of Induced Pluripotent Stem Cells with Novel Small Molecule Regulator$1,000,000
RC1 · FY2010 · GM · contact PI
Role of Angiogenesis and Endothelial Progenitor Cells in Diabetic Heart Failure$376,263
R01 · FY2010 · HL · contact PI
Identification of Novel Endothelial Progenitor Cells$193,750
R21 · FY2010 · HL · contact PI
Role of Angiogenesis and Endothelial Progenitor Cells in Diabetic Heart Failure$376,263
R01 · FY2009 · HL · contact PI
Myocardial Regeneration with Adult Stem Cells$367,420
R01 · FY2009 · HL · contact PI
Identification of Novel Endothelial Progenitor Cells$232,500
R21 · FY2009 · HL · contact PI
Role of Angiogenesis and Endothelial Progenitor Cells in Diabetic Heart Failure$375,959
R01 · FY2008 · HL · contact PI
Myocardial Regeneration with Adult Stem Cells$272,250
R01 · FY2008 · HL · contact PI
Myocardial Regeneration with Adult Stem Cells$118,874
R01 · FY2008 · HL · contact PI
Myocardial Regeneration with Adult Stem Cells$116,250
R01 · FY2008 · HL · contact PI
Role of Angiogenesis and Endothelial Progenitor Cells in Diabetic Heart Failure$412,675
R01 · FY2007 · HL · contact PI
Myocardial Regeneration with Adult Stem Cells$391,124
R01 · FY2007 · HL · contact PI
Role Angiogenesis/Endothelial Progenitor Cells Diabetic$425,000
R01 · FY2006 · HL · contact PI
Myocardial Regeneration with Adult Stem Cells$402,806
R01 · FY2006 · HL · contact PI
Myocardial Regeneration with Adult Stem Cells$412,500
R01 · FY2005 · HL